Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories

@article{vanLaar1995PharmacokineticsAC,
  title={Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories},
  author={Teus van Laar and Ernst N. H. Jansen and Cees Neef and Meindert Danhof and Raymund A. C. Roos},
  journal={Movement Disorders},
  year={1995},
  volume={10}
}
The pharmacokinetics and clinical effects of apomorphine after rectal administration were determined in five patients with idiopathic Parkinson's disease (PD). Three different pharmaceutical formulations were tested: a rectal solution of apomorphine (10 or 15 mg), a gelatin suppository (25 and 50 mg), and a Witepsol‐H15 suppository (50 and 100 mg). The pharmacokinetics of apomorphine were determined by measuring plasma concentrations using a sensitive and specific high‐performance liquid… 
Pharmacokinetic-Pharmacodynamic Relationships of Apomorphine in Patients with Parkinson’s Disease
TLDR
The population pharmacokinetic-pharmacodynamic data reflect the clinical observations of steep dose-effect curves if apomorphine is used in patients with random ‘on-off’ fluctuations and could be helpful in predicting the clinical effects of apomorphicine in the several subgroups of patients with Parkinson’s disease.
Other formulations and future considerations for apomorphine for subcutaneous injection therapy
TLDR
Although the diagnostic confirmation potential of this agent has been questioned, the drug may have an important role in evaluating the potential for benefit in the deep brain stimulation surgical setting.
Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment.
TLDR
Clinical improvement was observed and transdermal iontophoretic delivery of R-apomorphine in combination with surfactant pretreatment in patients with advanced Parkinson's disease, and the pharmacokinetics, pharmacodynamic effects, systemic and local side effects were assessed.
Apomorphine in the treatment of Parkinson disease and other movement disorders
TLDR
Subcutaneous apomorphine is well tolerated when co-administered with trimethobenzamide or domperidone premedication and has a unique efficacy as a ‘rescue’ medication owing to its rapid onset of action.
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
TLDR
The current symptomatic treatment of Parkinson’s disease mainly relies on agents which are able to restore dopaminergic transmission in the nigrostriatal pathway, such as the dopamine precursor levodopa or direct agonists of dopamine receptors, and future strategies should focus on the search for pharmacological agents with a better kinetic profile.
Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone.
TLDR
The use of parenteral apomorphine with rectal domperidone in the immediate postoperative period for patients unable to take oral antiparkinson drugs increases patient comfort, facilitates nursing care and may reduce serious postoperative complications.
Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease
TLDR
It is concluded that Apo‐MTD is absorbed and demonstrates clinical efficacy and long action, and seems a promising add‐on treatment for uncontrolled prolonged off phases in PD patients, but chronic tolerability needs further study.
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
  • D. Nyholm
  • Medicine
    Clinical pharmacokinetics
  • 2006
TLDR
In general, initial dopamine receptor agonist monotherapy is associated with poorer motor performance and lower incidence of motor complications compared with levodopa, and CDS can be approached by optimising the use of dopaminergic drugs based on pharmacokinetic data.
Old Drugs, New Delivery Systems in Parkinson’s Disease
TLDR
This review aims to provide up-to-date information about the newer delivery options for drugs used for Parkinson’s disease and provides a summary of infusion therapy with apomorphine, modifications to other dopamine agonists, various oral formulations of carbidopa/levodopa, inhaled levodOPA, intrajejunal infusion of levod opium, and sublingual apomorphicine.
Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up
TLDR
Subcutaneous apomorphine is a highly effective treatment which can substantially improve the symptomatology in patients with advanced stage Parkinson’s disease over a prolonged period of time.
...
1
2
3
4
...

References

SHOWING 1-10 OF 17 REFERENCES
Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
TLDR
The results indicated that SL apomorphine can reduce severe off periods in parkinsonian patients when used chronically, and its long-term use is limited by a severe side effect (stomatitis).
Peripheral pharmacokinetics of apomorphine in humans
TLDR
It is concluded that apomorphine is rapidly and completely absorbed from subcutaneous tissue, correlating with the rapid onset of clinical effects, and that the brief duration of clinical action of the drug is explained by its rapid clearance.
Subcutaneous apomorphine in the treatment of Parkinson's disease.
TLDR
Subcutaneous apomorphine is proposed as an effective treatment for patients with incapacitating "off" period disabilities refractory to oral medication and should be considered before experimental implantation procedures.
Time course of tolerance to apomorphine in parkinsonism
TLDR
It is concluded that tolerance to apomorphine occurs in parkinsonism, and the loss of response is greater after longer periods of drug administration.
SUBCUTANEOUS APOMORPHINE IN PARKINSONIAN ON-OFF OSCILLATIONS
TLDR
Results confirm that during off periods dopamine receptors remain responsive to stimulation and provide evidence of a new, effective, and well-tolerated treatment for the most disabling complication of long-term levodopa therapy.
Intranasal apomorphine in parkinsonian on-off fluctuations.
TLDR
The simplicity in the technique of intranasal apomorphine administration was found to be superior by all patients and the speed and the quality of motor response and the pharmacokinetic profile showed results similar to those seen after subcutaneous injection of apomorphicine administered by insulin pen syringe.
Disposition of morphine and its glucuronide metabolites after oral and rectal administration: Evidence of route specificity
TLDR
The data suggest that rectal administration of morphine is associated with significant avoidance of hepatic biotransformation, and they provide a convincing argument for the evaluation of morphine‐6‐glucuronide concentrations in pharmacokinetic and pharmacodynamic comparisons involving different routes of morphine administration.
Rectal apomorphine: a new treatment modality in Parkinson's disease.
TLDR
The evidence suggests that this patient with Munchausen's syndrome has repeatedly been admitted to hospital for investigation of acute headache and left hemiparesis and has undergone repeated radiological investigations and lumbar puncture.
The motor response to sequential apomorphine in parkinsonian fluctuations.
TLDR
The results suggest that rapid changes in receptor sensitivity during repeated intermittent dopaminergic stimulation do not contribute to the pathogenesis of Parkinson's disease and levodopa-induced motor fluctuations.
Intranasal apomorphine: a new treatment in Parkinson's disease.
TLDR
The initial downward gaze palsy indicates a bilateral involvement of the upper mesencephalon, which can be compared to Wernicke's encephalopathy where hypothermia may occur, and where the mesodiencephalic lesions, although more extended rostro-caudally, are bilateral.
...
1
2
...